<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841382</url>
  </required_header>
  <id_info>
    <org_study_id>REDD-0018</org_study_id>
    <nct_id>NCT04841382</nct_id>
  </id_info>
  <brief_title>Physician Assessment of the Clinical Utility of a Patient-Specific 3D Electro-Anatomical Heart Model in VT Ablation</brief_title>
  <acronym>ACE-VT</acronym>
  <official_title>Physician Assessment of the Clinical Utility of a Patient-Specific 3D Electro-Anatomical Heart Model in VT Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioSolv Ablation Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioSolv Ablation Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ACE-VT is a clinical pilot study designed to evaluate the ability of the CardioSolv Software&#xD;
      System to generate an output for the physician to review in a timely fashion, consistent with&#xD;
      the standard of care VT ablation workflow. This study will assess the acute effectiveness of&#xD;
      using the CardioSolv Software System output as additional supporting information during&#xD;
      ablation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Receipt of 3D Heart Model</measure>
    <time_frame>24 hours</time_frame>
    <description>Verify that the CardioSolv Software System is able to receive and process input data and generate the expected output available for viewing by the physician in less than 24 hours.</description>
  </primary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Ischemic Monomorphic Ventricular Tachycardia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supporting information.</intervention_name>
    <description>CardioSolv Software System is a software-based medical device meant which creates a patient-specific 3D heart model that provides physiologic information.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with monomorphic VT secondary to ischemic cardiomyopathy scheduled for a VT&#xD;
        ablation procedure will be considered for enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant meets standard criteria for VT ablation and is scheduled for VT ablation&#xD;
             by their cardiologist or electrophysiologist&#xD;
&#xD;
          2. 18 to 85 years of age&#xD;
&#xD;
          3. VT and ischemic cardiomyopathy&#xD;
&#xD;
          4. A pre-procedure MRI with LGE is available (performed within 1 year of procedure,&#xD;
             unless an MI has occurred since MRI) with adequate image for analysis&#xD;
&#xD;
          5. Participant is able and willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contradiction to MRI (except those with MRI compatible pacemaker/ICD/CRT devices&#xD;
             implanted or site has approved procedure for MRI of non-compatible devices).&#xD;
&#xD;
          2. Participant implanted with an LVAD.&#xD;
&#xD;
          3. Enrolled in another non-imaging intervention assignment study that could confound the&#xD;
             results of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saman Nazarian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark J Schwartz</last_name>
    <phone>443-692-9393</phone>
    <email>clinicalsupport@cardiosolv.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Upenn</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saman Nazarian, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

